Lanreotide powder for suspension for injection 30mg
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Powder for suspension for injection of lanreotide (as lanreotide acetate).
Acromegaly : Symptomatic relief
Symptomatic treatment of neuroendocrine (particularly carcinoid) tumours
Treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Hormone (IGF-1) remain abnormal after surgery and/or radiotherapy.
Treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumours.
Treatment of thyrotrophic adenomas when the circulating level of Thyroid Stimulating Hormone (TSH) remains inappropriately high after surgery and/or radiotherapy.
This monograph relates only to lanreotide powder for suspension for injection. A different formulation of lanreotide as a solution for injection is available and the separate monograph should be consulted.
Acromegaly and Neuroendocrine Tumours:
Initially, one 30mg intramuscular injection once every 14 days. The frequency of subsequent injections may be varied according to patient's response (as judged by a reduction in symptoms and/or a reduction in GH and/or IGF-1 levels), such that injections can be given every 7-10 days as necessary.
Treatment should only be initiated and maintained by physicians experienced in the management of this condition.
Initially, one intramuscular injection should be given every 14 days. In the case of an insufficient response (as judged by the levels of circulating thyroid hormone and TSH) the frequency of injection may be increased to one every 10 days. Periodic measurement of thyroid hormone and TSH levels should guide continued treatment.
For intramuscular injection.
Rotation of the injection site is recommended.
Children under 18 years
Precautions and Warnings
Advise ability to drive/operate machinery may be affected by side effects
Treatment to be initiated and supervised by a specialist
Monitor gall bladder ECHO before treatment & as clinically indicated after
Diabetic control may need adjustment
Monitor blood glucose
Monitor for signs of pituitary tumour expansion
Monitor thyroid function where clinically indicated
Discontinue treatment if cholelithiasis complications are suspected
May affect the absorption of concomitant oral drugs
Patients treated with lanreotide may experience hypoglycaemia or hyperglycaemia. Therefore, blood glucose levels should be monitored in all patients when lanreotide treatment is initiated or the dose altered. In diabetic patients insulin or oral antidiabetic requirements should be adjusted accordingly. Patients with underlying cardiac problems may experience a decreased heart rate without necessarily reaching the threshold of bradycardia. In patients with cardiac disorders prior to treatment, sinus bradycardia may occur. Caution is advised with treatment of lanreotide in patients with bradycardia. An additive effect on the reduction of heart rate may be seen as a result of concomitant administration and dose adjustments of such coadministered drugs may be necessary. Lanreotide may reduce gall bladder motility and lead to gallstone formation. Complications such as cholecystitis, cholangitis and pancreatitis, requiring cholecystemctomy have been reported. Gall bladder echography is advisable before treatment and as clinically indicated, or at six to twelve monthly intervals, thereafter. Exclude the presence of obstructive intestinal tumours in patients with carcinoid tumours before prescribing lanreotide. The gastrointestinal effects of lanreotide may reduce the intestinal absorption of co-administered drugs. Slight decreases in thyroid function have been seen during treatment with lanreotide in acromegalic patients, although clinical hypothyroidism is rare. Tests of thyroid function should be done where clinically indicated. Growth hormone-secreting pituitary tumours can expand during treatment with somatostatin analogues. Patients should be monitored for signs of tumour expansion (e.g. visual field defects).
Pregnancy and Lactation
Use lanreotide with caution during pregnancy.
The manufacturer advises lanreotide should be administered to pregnant women only if clearly needed. Data on a limited number of exposed pregnancies indicate no adverse effects of lanreotide on pregnancy or on the health of the new born child. Schaefer states that inadvertent use during pregnancy is not grounds for either termination or invasive diagnostic procedures. Studies in animals showed no evidence of teratogenic effects associated with lanreotide powder for suspension for injection during organogenesis.
Use lanreotide with caution during breastfeeding.
The manufacturer recommends exercising caution when using lanreotide during breastfeeding. It is unknown whether lanreotide is excreted in human breast milk. Schaefer suggests that due to the low oral bioavailability of hypothalamic and pituitary hormones, toxic effects are not expected in nursing infants and therefore use for appropriate indications during breastfeeding is acceptable.
Alterations in hepatic enzymes
Alterations in pancreatic enzymes
Decreased serum sodium
Increase in alkaline phosphatase
Increased glycated haemoglobin (HbA1c) levels
Injection site reactions
Serum bilirubin increased
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: September 2019
Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 3rd edition (2015) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.
Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Accessed on 16 September 2019.
Martindale: The Complete Drug Reference. 39th Edition. London: Brayfield A (ed). Pharmaceutical Press; 2017.
Summary of Product Characteristics: Somatuline LA. Ipsen Ltd. Revised December 2019.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.